Clinical trial NCT03469960: Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
Official title: A Randomized Phase 3 Trial Comparing Continuation Nivolumab-Ipilimumab Doublet Immunotherapy Until Progression Versus Observation in Treatment-naive Patients With PDL1-positive Stage IV Non-Small Cell Lung Cancer (NSCLC) After Nivolumab-Ipilimumab Induction Treatment
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Non-Small Cell Lung Cancer Metastatic
Keywords: IFCT
DICIPLE
NSCLC
Lead sponsor: Intergroupe Francophone de Cancerologie Thoracique
Sponsor class: OTHER
First posted: 2018-03-19
Enrollment: 265
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Non Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World. For the patients presenting a NSCLC stage IV, the median of survival is about 15 months today. The chemotherapy with platinum is the standard treatment for these patients but immunotherapy showed these efficacy in 1st line for patients PD-L1 positive. On the other hand, the duration of treatment by immunotherapy is not clear. Indeed, prolonged responses and long survivals have been described in patients having interrupted the treatment. In the melanoma, a treatment of 6 months of ipilimumab demonstrated its efficacy. The objective of the study is to demonstrate that a treatment of 6 months followed by an observation (stop and go) is not less effective than a treatment given until progression or toxicity. This strategy would allow to decrease the accumulated toxicities, to improve the quality of life of the patients and to decrease the costs.


Eligibility criteria: Inclusion Criteria:

1. Signed Written Informed Consent:

   Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care.

   Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.
2. Histologically-proven NSCLC (squamous or non-squamous)
3. Stage IV (M1, including M1a pleural involvement) disease (8th classification TNM, UICC 2015)
4. ECOG PS \< 1
5. Weight loss\< 10% in previous 3 months
6. No prior systemic anticancer therapy (including EGFR or ALK inhibitors) given as primary therapy for advanced or metastatic disease.
7. Age≥ 18 years, \<75 years
8. Life expectancy \> 3 months
9. Measurable tumor disease by CT or MRI per RECIST 1.1 criteria
10. Available tumor samples for centralized PD-L1 immunohistochemistry analysis
11. PD-L1 tumor content ≥ 1% and \< 50% tumor cells as assessed locally by the investigator center
12. Adequate biological functions:

    Creatinine Clearance ≥ 50 mL/min (Cockcroft or MDRD or CKD-epi); neutrophiles ≥ 1500/mm3 ; platelets ≥100 000/mm3 ; Hemoglobin ≥ 9g/dL ; hepatic enzymes \< 3x ULN, total bilirubin ≤ 1,5 x ULN except for patients with proved, Gilbert syndrome (≤ 5 x ULN) or patients with hepatic metastases (≤ 3,0 mg/dL)
13. Women of childbearing potential (WOCBP) and sexually active should use an efficacious contraception method within the 28 days preceding the first dose and during the 6 months following the last dose of treatment. Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.

    For Male subjects who are sexually active with WOCBP, an efficacious contraception method should be used during the treatment and during the 7 months following the last dose.

    Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception. Highly effective methods of contraception have a failure rate of \< 1% when used consistently and correctly. At a minimum, subjects must agree to the use of two methods of contraception, with one method being highly effective and the other method being either highly effective or less effective.
14. Patient inclusion validated by a multidisciplinary meeting.

Exclusion Criteria:

1. Small cell lung cancer or tumors with mixt histology including a SCLC component
2. Known EGFR activating tumor mutation (deletion LREA in exon 19, L858R ou L861X mutations in exon 21, G719A/S mutation in exon 18) or HER exon 20 insertion (either tissue or plasma cfDNA mutation).
3. Known ALK or ROS1 gene rearrangement as assessed by immunohistochemistry, FISH or NGS sequencing
4. Previous or active cancer within the previous 5 years (except for treated carcinoma in situ of the cervix or basal cell skin cancer). Patients with a prostate adenocarcinoma history within the previous 5 years could be included in case of localized prostate cancer, with good prognostic factors according to d'Amico classification (≤ T2a and Score de Gleason ≤ 6 and PSA (ng/ml) ≤ 10), provided they were treated in a curative way (surgery or radiotherapy, without any chemotherapy)
5. Superior vena cava (SVC) syndrome persisting after SVC stenting
6. Thoracic radiotherapy needed at initiation of tumor treatment, except bone palliative radiotherapy on a painful or compressive metastasis, respecting 4 weeks delay between the end of radiotherapy and the beginning of induction immunotherapy treatment
7. Symptomatic untreated brain metastasis (without previous whole brain radiotherapy or stereotactic ablative brain radiotherapy or without surgical resection). At least 4 weeks delay between the end of radiotherapy and the beginning of induction immunotherapy treatment should be respected. Asymptomatic brain metastasis, not needing corticosteroids greater than 10 mg prednisone equivalent daily or mannitol infusions, with no evolution on brain MRI or CT-scan within the previous month are allowed.
8. History of previous primary immunodeficiency, organ transplantation needing an immunosuppressive treatment, any immunosuppressive drug within 28 days before randomization date, or history of severe toxicity (grade 3/4) by immune mechanism linked to another immunotherapy treatment.
9. Systemic treatment with corticosteroids with greater dose than 10 mg prednisone equivalent daily, within 14 days before initiation of the immunotherapy induction. Inhaled, nasal or topic corticosteroids are allowed.
10. History of active autoimmune disease including rheumatoid polyarthritis, Lupus, Wegener disease. Patients with type I diabetes, or hypothyroidism, or immune cutaneous disease (vitiligo, psoriasis, alopecia) not needing any immunosuppressive systemic treatment, are allowed to be included.
11. Active inflammatory intestinal disease (diverticulosis, Crohn disease, Hemorrhagic recto-colitis, coeliac disease) or any serious chronic intestinal disease with uncontrolled diarrhea
12. Active uncontrolled infection including tuberculosis, known acute viral hepatitis B and C according to serological tests. Patients with serological sequelae of cured viral hepatitis are allowed to be included.
13. HIV known infection
14. Living attenuated vaccine received within the 30 previous days
15. Previous treatment with anti-PD-1, anti-PD-L1 or Anti-CTLA4 antibody
16. Previous treatment with chemotherapy
17. General serious condition such as congestive uncontrolled cardiac failure, uncontrolled cardiac arrythmia, uncontrolled ischemic cardiac disease (unstable angina or history of myocardial infarction in the previous 6 months), history or stroke within the 6 previous months
18. Pre-existing lung interstitial disease as assessed by the diagnosis CT-scan.

Primary outcomes:
measure: Progression Free Survival (PFS1)
timeFrame: 24 months after randomization of the last subject
Secondary outcomes:
measure: Progression Free Survival (PFS2)
timeFrame: 24 months after randomization of the last subject
measure: Quality of life (QoL)
timeFrame: 24 months after randomization of the last subject
measure: Overall survival (OS)
timeFrame: 6, 12 and 18 months after randomization
measure: Biological correlative exploratory studies (PD-L1)
timeFrame: 6 months
measure: Biological correlative exploratory studies (PD-L1 H score)
timeFrame: 6 months
measure: Biological correlative exploratory studies (CD3/CD8)
timeFrame: 6 months
measure: Biological correlative exploratory studies (neutrophil)
timeFrame: 6 months
measure: Biological correlative exploratory studies (cytokines)
timeFrame: 6 months
measure: Biological correlative exploratory studies (chemokines)
timeFrame: 6 months
Other outcomes:
Locations:
city: Amiens
country: France
facility: Amiens - CHU
city: Angers
country: France
facility: Angers - CHU
city: Annecy
country: France
facility: Annecy - CH
city: Argenteuil
country: France
facility: Argenteuil -CH
city: Avignon
country: France
facility: Avignon - CH
city: Bordeaux
country: France
facility: Bordeaux - Polyclinique Nord
city: Boulogne-Billancourt
country: France
facility: Boulogne - Ambroise Paré
city: Caen
country: France
facility: Caen - CHU Côte de Nacre
city: Cahors
country: France
facility: Cahors - CH
city: Cergy Pontoise
country: France
facility: CH de Pontoise
city: Chambery
country: France
facility: CH Chambery
city: Chauny
country: France
facility: CH de Chauny
city: Cholet
country: France
facility: CH
city: Clamart
country: France
facility: Clamart - Hôpital Percy
city: Clermont Ferrand
country: France
facility: Clermont Ferrand - CHU
city: Colmar
country: France
facility: Colmar - CH
city: Dijon
country: France
facility: Dijon - CAC
city: Grenoble
country: France
facility: CHRU Grenoble
city: La Roche Sur Yon
country: France
facility: La Roche Sur Yon - CH
city: Le Mans
country: France
facility: Centre Hospitalier - Pneumologie
city: Lille
country: France
facility: CHRU de Lille
city: Limoges
country: France
facility: CHU de Limoges
city: Lyon
country: France
facility: CH Lyon Sud - Pneumologie
city: Marseille
country: France
facility: Institut Paoli Calmette
city: Marseille
country: France
facility: Marseille - Hôpital Européen
city: Mont de Marsan
country: France
facility: Mont de Marsan - CH
city: Mulhouse
country: France
facility: Mulhouse - CH
city: Nantes
country: France
facility: Nantes - Centre René Gauducheau
city: Nice
country: France
facility: Centre Antoine Lacassagne
city: Nîmes
country: France
facility: CHU Nîmes
city: Orléans
country: France
facility: Orléans - CH
city: Paris
country: France
facility: AP-HP Hopital Tenon - Pneumologie
city: Paris
country: France
facility: AP-HP Hôpital Bichat
city: Paris
country: France
facility: GH Paris Saint-Joseph
city: Paris
country: France
facility: Hôpital Saint Louis APHP
city: Paris
country: France
facility: Paris - Institut Curie
city: Rouen
country: France
facility: Rouen - CHU
city: Saint Quentin
country: France
facility: Saint Quentin - CH
city: Saint-Cloud
country: France
facility: Centre René Huguenin
city: Saint-Mandé
country: France
facility: HIA Begin
city: Saint-Priest-en-Jarez
country: France
facility: ICL Lucien Neuwirth
city: Suresnes
country: France
facility: Suresnes - Hopital Foch
city: Toulon
country: France
facility: Toulon - CHI
city: Toulouse
country: France
facility: CHU Toulouse
city: Tours
country: France
facility: CHRU de Tours
city: Versailles
country: France
facility: Versailles - CH
city: Villefranche
country: France
facility: CH de Villefranche - Pneumologie
Study officials:
References: